Literature DB >> 19070896

The two stage model of preeclampsia: variations on the theme.

J M Roberts1, C A Hubel.   

Abstract

The Two Stage Model of preeclampsia proposes that a poorly perfused placenta (Stage 1) produces factor(s) leading to the clinical manifestations of preeclampsia (Stage 2). Stage 1 is not sufficient to cause the maternal syndrome but interacts with maternal constitutional factors (genetic, behavioral or environmental) to result in Stage 2. Recent information indicates the necessity for modifications of this model. It is apparent that changes relevant to preeclampsia and other implantation disorders can be detected in the first trimester, long before the failed vascular remodeling necessary to reduce placental perfusion is completed. In addition, although the factor(s) released from the placenta has usually been considered a toxin, we suggest that what is released may also be an appropriate signal from the fetal/placental unit to overcome reduced nutrient availability that cannot be tolerated by some women who develop preeclampsia. Further, it is evident that linkage is not likely to be one factor but several, different for different women. Also although the initial model limited the role of maternal constitutional factors to the genesis of Stage 2, this does not appear to be the case. It is evident that the factors increasing risk for preeclampsia are also associated with abnormal implantation. These several modifications have important implications. An earlier origin for Stage 1, which appears to be recognizable by altered concentrations of placental products, could allow earlier intervention. The possibility of a fetal placental factor increasing nutrient availability could provide novel therapeutic options. Different linkages and preeclampsia subtypes could direct specific preventive treatments for different women while the role of maternal constitutional factors to affect placentation provides targets for prepregnancy therapy. The modified Two Stage Model provides a useful guide towards investigating pathophysiology and guiding therapy.

Entities:  

Mesh:

Year:  2008        PMID: 19070896      PMCID: PMC2680383          DOI: 10.1016/j.placenta.2008.11.009

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  40 in total

1.  Is oxidative stress the link in the two-stage model of pre-eclampsia?

Authors:  J M Roberts; C A Hubel
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

Review 2.  How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview.

Authors:  P F Chien; N Arnott; A Gordon; P Owen; K S Khan
Journal:  BJOG       Date:  2000-02       Impact factor: 6.531

3.  Higher risk of pre-eclampsia after change of partner. An effect of longer interpregnancy intervals?

Authors:  O Basso; K Christensen; J Olsen
Journal:  Epidemiology       Date:  2001-11       Impact factor: 4.822

4.  Uterine artery Doppler flow and uteroplacental vascular pathology in normal pregnancies and pregnancies complicated by pre-eclampsia and small for gestational age fetuses.

Authors:  M W Aardema; H Oosterhof; A Timmer; I van Rooy; J G Aarnoudse
Journal:  Placenta       Date:  2001-05       Impact factor: 3.481

5.  First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.

Authors:  C Y Ong; A W Liao; K Spencer; S Munim; K H Nicolaides
Journal:  BJOG       Date:  2000-10       Impact factor: 6.531

6.  Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study.

Authors:  H U Irgens; L Reisaeter; L M Irgens; R T Lie
Journal:  BMJ       Date:  2001-11-24

7.  Activation of leukocytes during the uteroplacental passage in preeclampsia.

Authors:  Jan Roar Mellembakken; Pål Aukrust; Mette Kløvstad Olafsen; Thor Ueland; Kjetil Hestdal; Vibeke Videm
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

8.  Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia.

Authors:  Makrina D Savvidou; Aroon D Hingorani; Dimitrios Tsikas; Jürgen C Frölich; Patrick Vallance; Kypros H Nicolaides
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

9.  Sperm exposure and development of preeclampsia.

Authors:  Jon I Einarsson; Haleh Sangi-Haghpeykar; Michael O Gardner
Journal:  Am J Obstet Gynecol       Date:  2003-05       Impact factor: 8.661

10.  A longitudinal study of biochemical variables in women at risk of preeclampsia.

Authors:  Lucy C Chappell; Paul T Seed; Annette Briley; Frank J Kelly; Beverley J Hunt; D Stephen Charnock-Jones; Anthony I Mallet; Lucilla Poston
Journal:  Am J Obstet Gynecol       Date:  2002-07       Impact factor: 8.661

View more
  221 in total

1.  Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?

Authors:  Robert W Powers; James M Roberts; Daniel A Plymire; Dominick Pucci; Saul A Datwyler; Don M Laird; David C Sogin; Arun Jeyabalan; Carl A Hubel; Robin E Gandley
Journal:  Hypertension       Date:  2012-05-29       Impact factor: 10.190

2.  Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice.

Authors:  Ashley K Woods; Darren S Hoffmann; Christine J Weydert; Scott D Butler; Yi Zhou; Ram V Sharma; Robin L Davisson
Journal:  Hypertension       Date:  2010-11-15       Impact factor: 10.190

3.  Function of B-cell lymphoma 6 in trophoblast cells.

Authors:  Jie Li; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

4.  Multiple Soluble TGF-β Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF-β Signaling.

Authors:  Yao Wang; Qi Chen; Min Zhao; Kelly Walton; Craig Harrison; Guiying Nie
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

5.  TREM-1 expression is increased in human placentas from severe early-onset preeclamptic pregnancies where it may be involved in syncytialization.

Authors:  Ratana Lim; Gillian Barker; Martha Lappas
Journal:  Reprod Sci       Date:  2013-09-11       Impact factor: 3.060

Review 6.  Heightened susceptibility: A review of how pregnancy and chemical exposures influence maternal health.

Authors:  Julia Varshavsky; Anna Smith; Aolin Wang; Elizabeth Hom; Monika Izano; Hongtai Huang; Amy Padula; Tracey J Woodruff
Journal:  Reprod Toxicol       Date:  2019-05-02       Impact factor: 3.143

7.  Preeclampsia, placental insufficiency, and autism spectrum disorder or developmental delay.

Authors:  Cheryl K Walker; Paula Krakowiak; Alice Baker; Robin L Hansen; Sally Ozonoff; Irva Hertz-Picciotto
Journal:  JAMA Pediatr       Date:  2015-02       Impact factor: 16.193

8.  A potential role for allostatic load in preeclampsia.

Authors:  Vanessa J Hux; James M Roberts
Journal:  Matern Child Health J       Date:  2015-03

9.  Genetic dissection of the pre-eclampsia susceptibility locus on chromosome 2q22 reveals shared novel risk factors for cardiovascular disease.

Authors:  Matthew P Johnson; Shaun P Brennecke; Christine E East; Thomas D Dyer; Linda T Roten; J Michael Proffitt; Phillip E Melton; Mona H Fenstad; Tia Aalto-Viljakainen; Kaarin Mäkikallio; Seppo Heinonen; Eero Kajantie; Juha Kere; Hannele Laivuori; Rigmor Austgulen; John Blangero; Eric K Moses
Journal:  Mol Hum Reprod       Date:  2013-02-18       Impact factor: 4.025

10.  Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice.

Authors:  Jeremy A Sandgren; Guorui Deng; Danny W Linggonegoro; Sabrina M Scroggins; Katherine J Perschbacher; Anand R Nair; Taryn E Nishimura; Shao Yang Zhang; Larry N Agbor; Jing Wu; Henry L Keen; Meghan C Naber; Nicole A Pearson; Kathy A Zimmerman; Robert M Weiss; Noelle C Bowdler; Yuriy M Usachev; Donna A Santillan; Matthew J Potthoff; Gary L Pierce; Katherine N Gibson-Corley; Curt D Sigmund; Mark K Santillan; Justin L Grobe
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.